drug
ADBRY
updated 3mo agoby Leo Pharma AS
community read0 votes
🐶 often sniffed alongside
top 5all catalysts(0)
nothing on the calendar yet
Trials studying ADBRY
- phase2Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
- phase1A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects
- phase3A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- —Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
- phase3A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
- phase3Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
- phase3Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
- phase3Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
News(1)
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczemaInfinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.biopharma_dive · 6d ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that